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ABSTRACT 
Context  
Hyperthyroidism is associated with increased fracture risk, but it is not clear if lower TSH and higher free 
thyroxine (FT4) in euthyroid individuals are associated with fracture risk.  
Objective 
To evaluate the association of TSH and FT4 with incident fractures in euthyroid individuals.  
Design 
Individual participant data analysis. 
Setting 
Thirteen prospective cohort studies with baseline examinations between 1981 and 2002. 
Participants 
Adults with baseline TSH 0.45-4.49 mIU/L. 
Main Outcomes and Measures 
Primary outcome was incident hip fracture. Secondary outcomes were any, non-vertebral, and vertebral 
fractures. Results were presented as hazard ratios (HR) with 95% confidence interval (CI) adjusted for age and 
sex. For clinical relevance, we studied TSH according to five categories: 0.45-0.99mIU/L; 1.00-1.49mIU/L; 1.50-
2.49mIU/L; 2.50-3.49mIU/L; 3.50-4.49mIU/L (reference). FT4 was assessed as study-specific standard deviation 
increase, because assays varied between cohorts. 
Results 
During 659,059 person-years, 2,565/56,835 participants had hip fracture (4.5%; 12 studies with data on hip 
fracture). The pooled adjusted HR (95% CI) for hip fracture was 1.25 (1.05-1.49) for TSH 0.45-0.99mIU/L, 1.19 
(1.01-1.41) for TSH 1.00-1.49mIU/L, 1.09 (0.93-1.28) for TSH 1.50-2.49mIU/L, and 1.12 (0.94-1.33) for TSH 
2.50-3.49mIU/L (P for trend = 0.004). Hip fracture was also associated with FT4 (HR [95%CI] 1.22 [1.11-1.35] 
per one standard deviation increase in FT4). FT4 only was associated with any and non-vertebral fracture. 
Results remained similar in sensitivity analyses. 
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Conclusions 
Among euthyroid adults, lower TSH and higher FT4 are associated with an increased risk of hip fracture. These 
findings may help refine the definition of optimal ranges of thyroid function tests.  
 
Registration: The protocol was published on PROSPERO (registration number CRD42016039125) 
Primary funding source: Swiss National Science Foundation (SNSF 320030-150025). 
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INTRODUCTION 
 
Overt hyperthyroidism is a well-known risk factor for fractures and osteoporosis.1 We recently showed that 
subclinical hyperthyroidism was also associated with increased fractures incidence.2 Thyroid hormones 
stimulate bone turnover acting directly and indirectly on osteoclasts and osteoblasts.3 Anabolic action is net 
during growth, but in adults, catabolic action leads to greater bone loss and higher fractures risk.3 Thyroid 
hormones might also decrease muscular strength and coordination, and increase the risk of falls.4,5 
Administering TSH reduces bone resorption and increases bone formation.6 Conversely, high TSH levels can 
degrade bone quality by increasing cortical, rather than trabecular bone.  
The reference range for thyroid function – “euthyroidism” – is defined by the 95% confidence interval (CI) of a 
non-Gaussian distribution in an apparently healthy population. However, the studies from which this reference 
range was derived did not exclude participants with occult or underlying disease, e.g. those with positive anti-
thyroid antibodies, which might bias the reference range towards higher TSH values.7,8 In medicine, reference 
ranges can be derived from normative data, as for thyroid function, or preferably determining levels 
associated with important risks or outcomes, as for lipids, or blood pressure. 
TSH within the lower reference range has been associated with osteoporosis and fractures mostly in cross-
sectional studies of healthy post-menopausal women, but prospective data are limited and conflicting.5,9-13 If 
we can better understand the association between TSH and health outcomes, we could make more accurate 
estimates of fracture risk, which would help refine thyroxine treatment targets. We therefore aimed to assess 
the association between TSH within the reference range, FT4, and fractures risk by analyzing individual 
participant data (IPD) of population-based prospective cohort studies participating to the international Thyroid 
Studies Collaboration.2,14  
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METHODS 
 
Data source, searches and study selection  
The study protocol was registered on PROSPERO prior to study conduct (available on 
http://www.crd.york.ac.uk/PROSPERO; registration number: CRD42016039125). 
We updated our previous systematic literature search2 and searched for studies that may have included 
participants with only euthyroidism, which may have been omitted in our initial search. Our Ovid (MEDLINE) 
and EMBASE search (until 05/19/2016) used following medical search terms: euthyroid, euthyroidism or 
normal TSH and fractures or osteoporosis. After retrieving studies according to titles and abstracts, two 
authors (C.E.A. and D.S.) independently reviewed full-texts to confirm study eligibility. Disagreements were 
resolved by consensus with a third author (N.R.). We also requested unpublished fracture data from all cohorts 
of the Thyroid Studies Collaboration.2,14-17 Exclusion criteria were: 1) cohorts using first-generation TSH assays 
because these assays were not sensitive enough;18 2) studies with only participants aged <18 years; 3) studies 
with only participants with thyroid medication (thyroxine or anti-thyroid drugs); 4) studies with only 
participants with TSH outside the reference range (<0.45mIU/L or >4.49mIU/L); and, 5) studies exclusively on 
participants after thyroid surgery. Agreement between reviewers was 100% (K =1.00). 
 
Data extraction and quality assessment 
If the cohorts identified met our eligibility criteria, they were invited to provide IPD. Each study was approved 
by its local ethics committee. All participants gave informed consent for the original studies. We collected 
information on demographics, anthropometrics, medication, other risk factors for fractures, history of thyroid 
disorders, bone mineral density (BMD) and incident fractures. 
Risk of bias and study quality were independently assessed by C.E.A and D.S., using the following Newcastle-
Ottawa Quality Assessment Scale items:19 1) cohorts selection; 2) cohorts representativeness; 3) ascertainment 
of exposure; 4) availability of relevant confounding factors for adjustment; 5) outcome assessment based on 
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objective fractures assessment, with adjudication procedure for fractures other than hip; 6) length of follow-
up; 7) adequacy of follow-up; 8) researchers/participants/physicians blinding to thyroid values; and, 9) 
publication status. In sensitivity analyses, we excluded cohorts that did not meet one or more item(s). 
 
Data synthesis and analysis 
Definition of thyroid function 
To maximize comparability, we used uniform TSH thresholds based on previously established thresholds.2,14 
We defined euthyroidism as TSH 0.45-4.49mIU/L. For clinical relevance, we separated TSH values into five 
categories: 0.45-0.99mIU/L; 1.00-1.49mIU/L; 1.50-2.49mIU/L; 2.50-3.49mIU/L; 3.50-4.49mIU/L. The later was 
used as reference category because we hypothesized, based on our previous publication,2 that lower TSH 
might be associated with higher fractures risk.  Because of different FT4 reference ranges across studies, we 
used standard deviation (SD) rather than specific cut-offs. FT4 was available for all but two studies in the 
euthyroid range.20,21 
 
Definition of outcomes 
Our primary outcome was incident hip fracture, including femoral neck, pertrochanteric and subtrochanteric 
fractures, as previously defined.2 Briefly, we excluded pathologic (i.e. associated with metastasis or rare bone 
disease) and periprosthetic fractures.  Any, non-vertebral and clinical vertebral incident fractures were 
secondary outcomes. We excluded 1) vertebral fractures diagnosed with only radiologic imaging to keep focus 
on clinical relevance; 2) cervical and sacral vertebral fractures because fractures at these locations are usually 
associated with trauma rather than osteoporosis. “Any fractures” included fractures at any location, except for 
skull, face, ankle, finger or toe, since these are not related to osteoporosis. “Non-vertebral fractures” was the 
same as “any fractures” except it excluded vertebral fractures. For any and non-vertebral fractures, we 
excluded cohorts that collected fracture data on only part of the skeleton. Appendix table 1 describes 
fractures definitions by study. 
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Statistical analyses 
We used a shared frailty Cox regression model with random-effects at study level to conduct an IPD meta-
analysis, which used data from all included cohorts to assess the relationship of incident fractures with TSH 
categories and FT4, respectively.22,23  We used Schoenfeld residuals to test the proportional-hazards 
assumption.24 Results were presented as hazard ratios (HR) compared to the reference category . Time-to-
event was defined for each outcome from baseline TSH measurement to first fracture event. We adjusted 
primary analyses for age and sex, and then for other risk factors for fractures (body mass index [BMI], smoking, 
and history of diabetes), because they might mediate the association between thyroid function and fractures. 
We conducted following predefined sensitivity analyses: 1) excluding participants with thyroid medication 
(thyroxine or anti-thyroid medication) at baseline; 2) excluding participants with thyroid-altering medication at 
baseline (thyroid medication, oral corticosteroids, amiodarone, iodine); 3) excluding participants with anti-
fracture medication at baseline (bisphosphonate, calcitonin, selective estrogen receptor modulator, 
parathyroid hormone); 4) including only studies with formal fractures adjudication; 5) including only studies 
that uniformly defined fractures (except for hip fracture, since it has a common definition and is rarely 
reported in error); 6) excluding cohorts with loss to follow-up rates >5%; 7) excluding participants who 
developed overt or subclinical thyroid dysfunction over time; and 8) further adjusting for BMD as a potential 
mediator between thyroid function and incident fractures. In this last analysis, we included only studies that 
used dual energy X-ray absorptiometry (DXA) devices with femoral neck BMD (available for six studies)5,10,14,25-
27 for hip fractures, lumbar spine BMD (available for one study)10 for  vertebral fractures, and whole body BMD 
(available for one study)10  for any fractures. We conducted predefined stratified analyses by sex, age (<75 
versus ≥75 years) and duration of follow-up (<5 versus ≥5 years).  
For the FT4 analysis, we used the whole range of FT4 values including only participants with TSH within the 
reference range. FT4 values were converted to ng/mL (12.87pmol/L = 1ng/mL). We used study-specific SD to 
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assess fractures risk per one SD increase in FT4 because FT4 assays varied between cohorts.14 We performed 
the same sensitivity and stratified analyses as for TSH.  
We used STATA release 13.1 for all analyses (StataCorp LP, College Station, Texas). All tests were two-sided, at 
a 0.05 level of significance. 
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RESULTS 
 
Our updated literature search identified nine additional reports (Appendix figure 1).2 Eight of them concerned 
studies already identified in our previous search.2 The newly identified study (Study of Osteoporotic 
Fractures)20 agreed to participate.  We excluded the Nagasaki Adult Health Study,28 because it used first-
generation TSH assays, which have a low functional sensitivity (1mIU/L).18 For the same reason, this study had 
been included in our previous work2 in the analysis on subclinical hypothyroidism only, but not on subclinical 
hyperthyroidism.16  We included thirteen studies from the USA, Europe and Australia with 61,959 participants, 
and a median duration of follow-up of 12.1 years (interquartile range [IQR] 8.5-12.9), totaling 659,059 person-
years. Median age was 64 (range 18-102) with 60.5% women (Table 1). Median (IQR) TSH was 1.60mIU/L 
(1.10-2.30); 3.1% of participants used thyroid medication at baseline and 5.5% during follow-up; 17.7% had a 
TSH 0.45-0.99mIU/L, 24.8% 1.00-1.49mIU/L, 37.4% 1.50-2.49mIU/L, 14.2% 2.50-3.49mIU/L and 5.9% 3.50-
4.49mIU/L. Hip fracture occurred in 2,565 participants (4.6%; 12 studies), any fracture in 2,333 (8.9%; 9 
studies), non-vertebral fracture in 1,874 (8.5%; 9 studies), and vertebral fracture in 263 (1.3%; 7 studies). 
Overall quality was good (Appendix table 2):  one study reported loss to follow-up >5%,5 four did not perform  
formal fractures adjudication,26,29-31 and three had not published fractures data in a separate manuscript.17,29,30  
Tests of the proportional-hazards assumption on the basis of Schoenfeld residuals indicated that assumptions 
were met for all analyses (P > 0.11 for all). 
 
Thyroid function and hip fractures 
Compared with the reference group (TSH 3.50-4.49mIU/L), pooled age- and sex-adjusted HR (95% CI) for hip 
fractures was 1.25 (1.05-1.49) for TSH 0.45-0.99mIU/L, 1.19 (1.01-1.41) for TSH 1.00-1.49mIU/L, 1.09 (0.93-
1.28) for TSH 1.50-2.49mIU/L, and 1.12 (0.94-1.33) for TSH 2.50-3.49mIU/L (P for trend 0.004, Figure 1). After 
adjusting for smoking status, BMI, and history of diabetes, HR (95% CI) was 1.24 (1.03-1.49) for TSH 0.45-
0.99mIU/L compared with the reference group, while HR (95%CI) for TSH 1.00-1.49mIU/L was somewhat 
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attenuated and no longer statistically (1.15 [0.97-1.38]). The risk of hip fractures in participants with TSH 0.45-
0.99mIU/L remained significantly higher in all sensitivity analyses, and was even higher after adjusting for 
femoral neck BMD (Table 2). For TSH 1.00-1.49mIU/L, the risk of hip fractures remained significantly in all 
sensitivity analyses, except after adjusting for femoral neck BMD or after excluding participants with thyroid-
alterating medication at baseline. This association remained not significant for TSH 1.50-2.49mIU/L or TSH 
2.50-3.49mIU/L. We found no significant interaction for sex, age or duration of follow-up (Appendix figure 2), 
although confidence intervals were larger and point estimates smaller for age <75 years and follow-up <5 
years. Conversely, there was significant interaction for publication status with a HR (95% CI) of 1.35 (1.13-1.61) 
for the ten studies that published risk of hip fracture associated with thyroid function in a separate 
manuscript, and 0.44 (0.21-0.90) for the two studies17,29 that did not previously publish hip fracture data 
associated with thyroid function in a separate article (P for interaction 0.0001, Appendix table3). 
The HR (95% CI) for hip fractures was 1.24 (1.12-1.37) per one SD increase in FT4 (Figure 2).We found no 
significant interaction with sex, age, duration of follow-up, or publication status of hip fractures data (Figure 2, 
Appendix table 3), although point estimate was smaller when follow-up was <5 years. All sensitivity analyses 
yielded similar results (Table 2). In the 25,760 participants of the five cohorts with available data on thyroid 
function during follow-up,26,29-32 146 (0.6%) participants developed subclinical hyperthyroidism and 46 (0.2%) 
overt hyperthyroidism. When we included only endogenous forms of thyroid dysfunction (i.e., participants 
without thyroxine use at baseline, N=25,049), 102 (0.4%) and 25 (0.1%) participants developed subclinical and 
overt hyperthyroidism, respectively. The HR (95% CI) for hip fractures for TSH 0.45-0.99mIU/L compared with 
the reference group was 1.70 (1.13-2.57) in the sensitivity analysis including only participants with TSH 
remaining within the reference range (four  cohorts with data on hip fractures and thyroid function during 
follow-up).26,29,31,32 
 
Thyroid function and any, non-vertebral, and vertebral fractures 
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For all TSH categories when compared with the reference group, we found no significant association for any, 
non-vertebral, or vertebral fractures (Appendix Table 4). The HR (95% CI) per one SD increase in FT4 was 1.08 
(1.02-1.15) for any fractures, and 1.10 (1.03-1.18) for non-vertebral fractures. These associations remained 
significant in most sensitivity analyses (Table 3), except when adjusting for BMD. Association between FT4 and 
vertebral fractures was not statistically significant, possibly because of the lower number of data (Table 3). We 
found no significant interaction in the analyses stratified by sex, age, duration of follow-up, or publication 
status for any of these fractures outcomes (Table 3, Appendix table 3).  
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DISCUSSION 
 
In this analysis of 61,959 euthyroid participants of thirteen prospective cohorts, lower TSH within the 
reference range, particularly TSH 0.45-0.99mIU/L, was associated with increased risk of hip fractures, and 
higher FT4 with increased risk of hip, any, and non-vertebral fractures. 
While overt and subclinical hyperthyroidism have been associated with increased fractures risk,1,2 previous 
studies on the relationship between TSH within the reference range and fractures risk had conflicting results.   
The Clalit Health Services, a large historical cohort study, found a borderline increased incidence of hip fracture 
with TSH 0.35-1.6mIU/L when compared with TSH 1.7-2.9mIU/L, but in women only (odds ratio [95%CI] 1.28 
[1.03-1.59]), while the association with other osteoporotic fractures was not statistically significant.11  A small 
cross-sectional study (N=129) found an association between low TSH and vertebral fractures.12 The 
Cardiovascular Health Study found no significant association between TSH within the reference range or FT4 
assessed as continuous variables and hip fractures,13 but, consistent with our findings, curves bent with an 
increased fracture risk for TSH <1.5mIU/L and for FT4 >1.4ng/mL. Our thorough IPD analysis across multiple 
prospective cohorts confirms the association between low TSH and hip fractures, and an association between 
high FT4 and all but vertebral fractures in participants with TSH within the reference range, suggesting that 
even a modest increase in thyroid hormones among euthyroid adults is associated with higher fractures risk. 
Our study was strengthened, first, by an IPD analysis that allowed us to standardize the definitions of 
predictors and outcomes, adjust for similar potential confounders, and avoid aggregation bias for subgroup 
analyses. This was the best way to perform time-to-event analysis.33 Second, our study is the largest to assess 
fractures risk in prospective cohorts with TSH within the reference range. Third, we included all international 
prospective cohorts available on this topic, since all the studies we identified agreed to participate.  
Our study had several limitations. First, our population consisted mostly of Caucasians and included few young 
adults. Second, thyroid function was assessed only at baseline in most cohorts, so that we may have included 
adults who developed subclinical hyperthyroidism or overt thyroid dysfunction. However, our sensitivity 
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analysis including only participants with persistent TSH within the reference range yielded an even stronger 
association between low TSH and hip fractures. Third, fractures were adjudicated in 9/13 cohorts, and we 
could not uniformly define each fracture type across all cohorts. Nevertheless, sensitivity analyses limited to 
cohorts with the most uniform factures definitions or adjudicated fractures yielded similar results. Fourth, we 
did not know fractures mechanism, but we excluded pathological fractures and fractures locations typically not 
associated with osteoporosis to reduce bias related to traumatic fractures. Fifth, data on fractures other than 
hip were available in a more limited number of studies, reducing the number of outcomes and the related 
power to identify associations. 
Our findings have three important clinical implications. First, the TSH reference range is still a matter of 
debate; 34 some authors advocate narrowing of reference range,7,35 and others recommend against any 
change.8,36,37 TSH reference range was indeed defined in a population that included persons with occult or 
underlying thyroid disease.7,8 TSH between 0.4 and 2.5mIU/L is associated with a lower incidence of thyroid 
dysfunction,38 but previous studies and this present analysis showed various adverse outcomes associated 
with subclinical thyroid dysfunction,14-16,39-41 and with TSH at both extremities of the reference range (e.g. 
higher risk of cardiovascular diseases with high TSH/low FT4, higher risk of fractures, osteoporosis and 
dementia with low TSH/high FT4).9,13,42 There may be optimal values of thyroid function within the reference 
range. 
Second, similar to previous studies showing stronger association of adverse outcomes with FT4 than TSH,43,44 
FT4 was associated with hip, any and non-vertebral fractures, while TSH was associated only with hip 
fractures.  TSH and thyroid hormones may act differently on peripheral organs, including bones: TSH may act 
on osteoblasts and osteoclasts via specific receptors,3 while thyroid hormones may act on target tissues via 
nuclear receptors controlled locally by deiodinases.3,45,46  This may explain why TSH and FT4 are associated 
with different fractures types. FT4 may therefore help evaluate osteoporosis and fractures risk, which is now 
usually done with the World Health Organization FRAX score,47 but future studies should determine if adding 
FT4 improves clinical accuracy of this score. To note, FT4 was not significantly associated with vertebral 
15 
 
fractures. One explanation may be that FT4 acts differently on vertebral bones. It may however also be due to 
lack of power, as we could include about 10 times less vertebral than other fractures (Table 3). 
 Third, in patients with thyroid cancer, TSH should be maintained between 0.3-2.0mIU/L, 0.1-0.5mIU/L or even 
<0.1mIU/L for 5-10 years, depending on a risk/benefit assessment, based on patient’s response to treatment, 
consecutive risk of recurrence, and potential adverse effects of TSH suppression.48,49 Our findings suggest that 
fracture risk should be considered in this evaluation, particularly in low-risk patients, since they may be 
particularly exposed to long-term TSH suppression. 
We may have expected a stronger association of fractures with TSH and FT4, respectively, after excluding 
participants with thyroid medication at baseline, but the risk was only slightly increased, probably because of 
the low number of participants with thyroid medication at baseline (N=1897, 3%). 
In conclusion, analyzing individual data of 61,959 adults from thirteen large prospective cohorts, we found that 
low TSH within the reference range was associated with higher risk of hip fractures, and high FT4 with higher 
risk of hip, non-vertebral, and any fractures. Our findings may help refine the current definition of optimal 
thyroid function. Meanwhile, clinicians should be aware that lower TSH and higher FT4, even within the 
normal range, are associated with an increased risk of hip fracture.  
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Table 1. Study population and baseline characteristics of the participants in the 13 included studies (n=61,959). 
Study name,  
place 
Description of  
study population 
Number of 
participants 
Age, 
median 
(range) a 
Women, 
 No. (%) 
TSH, 
median, 
mIU/L 
Thyroid 
medication at 
baseline, No. 
(%) b,c 
Thyroid 
medication 
during follow-
up, No. (%) b,d 
Start of 
follow-up, 
year 
Duration of 
follow-up,  
median (IQR), 
years e 
Person-
Years 
Busselton Health 
Study, Australia29  
Adults 1,907 
51 (18-
90) 
919 (48.2) 1.42 10 (0.5) 15 (0.8) 1981 
20.0 (17.6-
20.0) 
33,281 
CHS, USA (4 
communities)26  
Adults with 
Medicare  
eligibility 
2,853 
71 (65-
100) 
1,694 (59.4) 2.03 145 (5.1) 299 (10.5) 1989-1990 12.9 (7.5-18.9) 36,466 
EPIC-Norfolk Study, 
England50  
Adults aged 45-
79y 
11,986 
58 (40-
78) 
6,365 (53.1) 1.70 275 (2.3) NA 1995-1998 
12.4 (11.7-
13.3) 
142,951 
Health ABC Study, 
USA (4 
communities)14  
Adults aged 70-
79y with Medicare 
eligibility 
2,347 
74 (69-
81) 
1,165 (49.6) 1.99 177 (7.5) 383 (13.9) 1997 12.7 (8.1-13.2) 24,794 
HUNT Study, 
Norway,32,f 
Adults 31,388 
57 (19-
99) 
21,186 (67.5) 1.60 999 (3.2) NA 1995-1997 
12.2 (11.6-
12.8) 
345,517 
InCHIANTI Study, 
Italy17  
 
Adults aged ≥65y 1,066 
71 (21-
102) 
590 (55.3) 1.38  17 (1.6) 28 (2.6) 1998 9.1 (7.8-9.3) 8,562 
Leiden 85-Plus Study, 
The Netherlands31 
Adults aged 85y 456 
85 (85-
85) 
293 (64.3) 1.66 6 (1.3) 11 (2.4) 1997-1999 4.8 (2.2-8.1) 2,411 
MrOS, USA (6 clinical 
centers)10 
Men aged ≥65y 1,410 
73 (65-
99) 
All men 1.97 83 (5.9) 98 (6.9) 2000-2002 11.1 (8.1-11.8) 13,568 
OPUS, Germany, 
France, UK5,g 
Women aged 20-
80y 
1,205 
63 (20-
80) 
All women 0.96 0 (0.0) NA 1999-2001 6.0 (5.8-6.3) 7,179 
PROSPER, Ireland, 
Scotland, The 
Netherlands30 
Older adults at 
high 
cardiovascular risk 
5,124 
75 (69-
83) 
2,527 (49.3) 1.75 135 (2.6) 163 (3.2) 1997-1999 3.2 (3.0-3.5) 15,833 
Rotterdam Study, The 
Netherlands51 
Adults aged ≥55y 1,611 
68 (55-
93) 
957 (59.4) 1.54 21 (1.3) NA 1989-1992 
15.2 (10.4-
16.2) 
21,130 
Sheffield Study, 
England27 
 
Women aged 50-
85y 
291 
63 (50-
86) 
All women 2.00 2 (0.7) 9 (3.1) 1990-1991 10.0 (5.5-10.1) 2,301 
SOF, USA (4 clinical 
centers) 20,h 
Women >65y 314 
71 (65-
88) 
All women 1.50 15 (4.8) NA 1986-1998 14.3 (9.8-19.8) 4,433 
Overall 13 cohorts 61, 959 
64 (18-
102) 
37,506 (60.5) 1.60 1,885 (3.1) 831 (5.5) 1981-2002 
12.1 (8.5-
12.9) 
659,059i 
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Abbreviations: CHS, Cardiovascular Health Study; EPIC, European Prospective Investigation of Cancer; Health ABC, Health, Aging and Body Composition, HUNT, Nord-
Trøndelag Health Study; InCHIANTI, Invecchiare in Chianti Study; IQR, interquartile range; MrOS, Osteoporotic Fractures in Men Study; No., number; OPUS, Osteoporosis 
and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone; UK, 
United Kingdom; USA, United States of America; y, years. 
a We excluded participants younger than 18y. 
b Thyroid medication was defined as thyroxine or anti-thyroid medication. 
c Data on thyroid medication at baseline was missing for 255 participants in the HUNT Study, 59 participants in MrOS, 1 participant in the Rotterdam Study, 4 participants 
in SOF and 7 participants in Health ABC Study. 
d Data on thyroid mediation at follow-up was missing for 243 participants in MrOS, 96 participants in InCHIANTI Study, 45 participants in Sheffield Study, and all 
participants in HUNT Study, EPIC-Norfolk Study, Rotterdam Study, OPUS and SOF. 
e Duration of follow-up was defined as the maximum duration of follow-up that was available, i.e. the time to the first hip (or any if unavailable) fracture or censor 
date/death. 
f We included participants excluded from the original article of HUNT Study (participants <40y, with previous fracture and/or with previous thyroid disease), which 
explains the different number of the sample. 
g We included only the thyroid hormone sub-study of OPUS, which excluded participants on thyroid medication. 
h We included only a subsample of SOF, i.e., the participants with TSH measurement at baseline. 
I It was calculated as time to hip fracture; for PROSPER, it was calculated as time to any fracture, since data on hip fracture was unavailable.  
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Table 2: Sensitivity analyses for the risk of hip fracture according to thyroid-stimulating hormone and free thyroxine  
 
 Analysis by TSH category a Analysis by SD increase in FT4 b 
No. of events/ 
participants 
Hazard ratio 
(95% CI) c 
No. of events/ 
participants 
Hazard ratio 
(95% CI) d 
Main analysis 610/13,390 1.25 (1.05-1.49) 542/20,633 1.24 (1.12-1.37) 
  Medication use 
  Excluding participants with thyroid medication at baseline e 557/12,728 1.28 (1.06-1.53) 526/20,158 1.26 (1.13-1.40) 
  Excluding participants with thyroid-altering medication at baseline f 542/12,396 1.28 (1.07-1.55) 506/19,679 1.26 (1.13-1.40) 
  Excluding participants with anti-fracture medication at baseline g 605/12,739 1.27 (1.07-1.52) 539/20,563 1.24 (1.12-1.38) 
  Definition of fracture 
   Including only studies with formal fracture adjudication h 496/12,048 1.31 (1.06-1.60) 416/17,913 1.21 (1.07-1.36) 
  Other  
   Excluding one study with loss to follow-up >5% i 606/12,748 1.26 (1.05-1.50) 536/19,463 1.24 (1.11-1.37) 
  BMD 
   Further adjusting for femoral neck BMD at baseline j 94/2,020 1.68 (1.08-
2.61)k 
142/4,147 1.22 (1.01-1.47) 
Abbreviations: BMI, body mass index; BMD, bone mineral density; CHS, Cardiovascular Health Study; CI, confidence interval; EPIC, 
European Prospective Investigation of Cancer; FT4, free thyroxine; Health ABC, Health, Aging and Body Composition; HUNT, Nord-
Trøndelag Health Study; InCHIANTI, Invecchiare in Chianti; MrOS, Osteoporotic Fractures in Men Study; No., number; OPUS, 
Osteoporosis and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SD, standard deviation; SOF, 
Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone. 
All analyses were adjusted for age (as a continuous variable) and sex. Data for hip fractures were available for 12 cohorts (all but 
PROSPER). 
                                                 
a We present a selected analysis for the TSH category 0.45-0.99mIU/L compared with the reference category (TSH 3.50-4.99mIU/L). 
b FT4 was measured in all studies but SOF and Health ABC Study (FT4 not measured in participants with TSH within reference range). 
c Hazard ratios are for TSH 0.45-0.99mIU/L, compared with the reference group 3.50-4.99mIU/L.  
d Hazard ratios are per one standard deviation increase in FT4. 
e Thyroid medication was defined as thyroxine or anti-thyroid medication. 
f Thyroid-altering medication included oral corticosteroid, amiodarone, iodine, thyroxine and/or anti-thyroid medication. 
g Anti-fracture medication was defined as bisphosphonate, calcitonin, selective estrogen receptor modulator and/or parathyroid hormone. 
h EPIC-Norfolk Study, HUNT Study, InCHIANTI Study, MrOS, OPUS, Rotterdam Study, Sheffield Study, Health ABC Study and SOF (Health ABC 
Study and SOF only in the TSH analysis). 
i OPUS. 
j Femoral neck BMD at baseline was available in following studies: CHS, MrOS, Rotterdam Study, Sheffield Study, OPUS, Health ABC Study. 
k Participants within the TSH category 3.50-4.49mIU/L had lower femoral neck BMD at baseline than participants within the TSH category 0.45-
1.50mIU/L (mean [SD]): 0.77g/cm2 (0.16) versus 0.79 g/cm2 (0.15) respectively, P = 0.002), which explains the higher hazard ratio after adjusting 
for femoral neck BMD at baseline.  
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Table 3. Sensitivity and stratified analyses for the risk of any, non-vertebral and vertebral fractures, per one standard deviation increase in free 
thyroxine  
 Any fracture a Non-vertebral fracture b Vertebral fracture c 
No. of 
events/ 
participants 
Hazard ratio 
(95% CI) 
No. of 
events/ 
participants 
Hazard ratio 
(95% CI) 
No. of events/ 
participants 
Hazard ratio 
(95% CI) 
Main analysis 1,629/22,977 1.08 (1.02-1.15) 1,273/19,101 1.10 (1.03-1.18) 129/17,711 1.06 (0.86-1.30) 
  SENSITIVITY ANALYSES 
  Medication use 
  Excluding participants with thyroid medication at baseline d 1,552/22,440   1.09 (1.02-1.16) 1,240/18,697 1.14 (1.06-1.23) 125/17,309 1.08 (0.86-1.37) 
  Excluding participants with thyroid-altering medication at 
baseline e 
1,537/21,976 1.09 (1.02-1.15) 1,200/18,256 1.11 (1.03-1.19) 125/16,868 1.07 (0.86-1.32) 
  Excluding participants with anti-fracture medication at 
baseline f 
1,622/22,927 1.08 (1.02-1.15) 1,263/19,038 1.10 (1.03-1.18) 127/17,666 1.05 (0.85-1.29) 
  Definition of fracture 
   Including only studies with formal fracture adjudication g 1,026/15,805 1.11 (1.02-1.19) 1,111/17,208 1.11 (1.03-1.19) 113/15,806 1.07 (0.86-1.32) 
   Including only studies with most uniform definition of 
fracture h 
1,155/19,728 1.06 (0.99-1.14) 685/14,461 1.08 (0.98-1.19) 65/14,462 1.10 (0.83-1.47) 
  Other  
  Further adjusting for smoking status, BMI and diabetes 
mellitus 
1,591/22,536 1.21 (1.00-1.46) 1,140/17,562 1.09 (1.01-1.18) 126/17,290 1.03 (0.83-1.27) 
  Excluding studies with loss of follow-up rate >5% NA NA 1,174/17,981 1.13 (1.04-1.22) NA NA 
  BMD 
   Further adjusting for lumbar spine BMD at  baseline i NA NA NA NA 39/1,399 0.96 (0.68-1.36) 
   Further adjusting for whole body BMD at baseline j 183/1,399 0.89 (0.75-1.04) NA NA NA NA 
  STRATIFIED ANALYSES 
  Stratified for sex  
                                                 
a Data on any fractures were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, PROSPER, Rotterdam Study, Busselton Health Study). 
b Data on non-vertebral fractures were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, Sheffield Study, OPUS). 
c Data on vertebral fractures were available for 5 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study). Vertebral fracture was 
defined as a clinical symptomatic dorsal or lumbar fracture. 
d Thyroid medication was defined as thyroxin or anti-thyroid drug. 
e Thyroid-altering medication included oral corticosteroid, amiodarone, iodine, thyroxin and/or anti-thyroid drug. 
f Anti-fracture medication was defined as bisphosphonate, calcitonin, selective estrogen receptor modulator and/or parathyroid hormone. 
g EPIC-Norfolk Study, HUNT Study, InCHIANTI Study, MrOS, OPUS, Rotterdam Study, Sheffield Study. 
h EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, MrOS, PROSPER. 
i Lumbar spine BMD was available in MrOS only. 
j Whole body BMD was available in MrOS only. 
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  Women 1,013/11, 321 1.11 (1.03-1.19) 827/10,075 1.10 (1.01-1.20) 62/8,679 1.12 (0.83-1.51) 
  Men 616/11,656 1.05 (0.95-1.15) 446/9,026 1.08 (0.96-1.22) 67/9,032 1.00 (0.75-1.33) 
P-value for interaction NA 0.39 NA 0.79 NA 0.61 
Stratified for age  
  <75 years at baseline 1,041/18,367 1.10 (1.02-1.19) 955/17,144 1.10 (1.02-1.20) 87/15,917 0.96 (0.74-1.25) 
  ≥75 years at baseline 588/4610 1.06 (0.96-1.16) 318/1,957 1.10 (0.97-1.25) 42/1,794 1.25 (0.88-1.76) 
P-value for interaction NA 0.47 NA 0.99 NA 0.25 
  Stratified for duration of follow-up  
  <5 years  446/5,920 1.04 (0.93-1.15) 47/888 0.82 (0.59-1.14) 7/888 0.60 (0.26-1.37) 
  ≥5 years  1,183/17,057 1.09 (1.02-1.18) 1,226/18,213 1.10 (1.03-1.18) 122/16,823 1.07 (0.87-1.33) 
P-value for interaction NA 0.39 NA 0.07 NA 0.18 
Abbreviations: BMD, bone mineral density; BMI, body mass index; CI, confidence interval; EPIC, European Prospective Investigation of Cancer; FT4, free 
thyroxine; Health ABC, Health, Aging and Body Composition; InCHIANTI, Invecchiare in Chianti Study; MrOS, Osteoporotic Fractures in Men Study; NA, not 
appropriate; No., number; OPUS, Osteoporosis and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SD, standard 
deviation; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone. 
All analyses were adjusted for age (as a continuous variable) and and sex; FT4 was measured in all studies but SOF and Health ABC Study (FT4 not 
measured in participants with TSH within the reference range). 
Hazard ratios are per one standard deviation increase in FT4. 
31 
 
Figures titles 
 
Figure 1.  
Risk of hip fracture according to thyroid-stimulating hormone categories  
 
Figure 2.  
Risk of hip fracture per one standard deviation increase in free thyroxine, overall and stratified by sex, 
age and duration of follow-up  
 
Figures captions 
 
Figure 1 
Abbreviations: CI, confidence interval; HR; hazard ratio; No., number; TSH, thyroid-stimulating hormone. 
Data on hip fractures were available for 12 studies (all except PROSPER). 
 
Figure 2 
Abbreviations: CI, confidence interval; FT4, free thyroxine; Health ABC, Health, Aging and Body 
Composition; HR; hazard ratio; No., Number; SOF, Study of Osteoporotic fractures, TSH, thyroid-stimulating 
hormone. 
The analysis stratified for sex was adjusted for age. All other analyses were adjusted for age (as a 
continuous variable) and sex. 
FT4 was measured in all studies but SOF and Health ABC Study (FT4 not measured in participants with TSH 
within the reference range).  
Data on hip fractures were available for 10 studies with measured FT4 (all except PROSPER). 
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Figure 1. Risk of hip fracture according to thyroid-stimulating hormone categories 
 
 
Abbreviations: CI, confidence interval; HR, hazard ratio; No., number; TSH, thyroid-stimulating hormone. 
Data on hip fractures were available for 12 studies (all except PROSPER). 
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Figure 2. Risk of hip fracture per one standard deviation increase in free thyroxine, overall and 
stratified by sex, age and duration of follow-up  
 
 
Abbreviations: CI, confidence interval; FT4, free thyroxine; Health ABC, Health, Aging and Body 
Composition; HR; hazard ratio; No., Number; SOF, Study of Osteoporotic fractures, TSH, thyroid-stimulating 
hormone. 
The analysis stratified for sex was adjusted for age. All other analyses were adjusted for age (as a 
continuous variable) and sex. 
FT4 was measured in all studies but SOF and Health ABC Study (FT4 not measured in participants with TSH 
within the reference range).  
Data on hip fractures were available for 10 studies with measured FT4 (all except PROSPER). 
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Appendix table 1. Definition of fractures in each study 
 
Study Hip fracture Any fracture Non-vertebral fracture Vertebral fracture 
Busselton Health Study ICD10: S72.0-1 
Non-vertebral or 
vertebral fracture (first 
event) 
Including: ICD9: 807-829. 
Excluding: skull/face 
(ICD9: 800-804) 
Clinically diagnosed; cervical (ICD10: 
S12), thoracic (ICD10: S22) or 
lumbar vertebrae (ICD10: S32), 
vertebrae of unknown location 
(ICD10: T08) 
CHS 
ICD9: 820.0-820.9 for inpatients, 
plus CPT procedure code on 
fracture treatment for outpatients 
NA NA NA 
EPIC-Norfolk Study ICD10: S72.0-2 
Non-vertebral or 
vertebral fracture (first 
event) 
Excluding skull/face, 
ankle, fingers, toes 
Clinically diagnosed; thoracic 
(ICD10: S22), lumbar vertebrae 
(ICD10: S32), vertebrae of unknown 
location (ICD10: T08) 
Health ABC Study 
Femoral neck, intertrochanteric, 
proximal femur 
Non-vertebral or 
vertebral fracture (first 
event) 
Excluding ankle, fingers, 
toes 
Clinically diagnosed; thoracic or 
lumbar vertebrae  
HUNT Study 
ICD9: 820.0-820.9, SIFF-95 
procedure codes; 
ICD10: S72.0-2, S72.9, NCSP codes 
NA NA NA 
InCHIANTI Study 
ICD9: 820.0-820.9 for inpatients, 
plus CPT procedure code on 
fracture treatment for outpatients 
Non-vertebral or 
vertebral fracture (first 
event) 
Excluding skull/face, 
ankle, fingers, toes 
Clinically diagnosed; thoracic (ICD9: 
805.2-5) or lumbar vertebrae (ICD9: 
806.2-5)  
Leiden 85-Plus Study Any hip fracture Any fracture NA NA 
MrOS 
Femoral neck, intertrochanteric, 
subtrochanteric 
Non-vertebral or 
vertebral fracture (first 
event) 
Excluding skull/face, 
ankle, fingers, toes 
Clinically diagnosed; thoracic or 
lumbar vertebrae  
OPUS Any low-traumatic hip fracture NA 
Any low-traumatic non-
vertebral fracture 
NA 
PROSPER NA Any fracture NA NA 
Rotterdam Study Any hip fracture 
Non-vertebral or 
vertebral fracture (first 
event) 
Excluding skull, 
ankle/foot, 
fingers/and/wrist 
Any clinically diagnosed vertebral 
fracture 
Sheffield Study Any hip fracture NA 
Any non-vertebral 
fracture 
NA 
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SOF 
Any hip fracture, excluding severe  
traumatic fracture 
Any fracture 
Any non-vertebral 
fracture, excluding 
severe traumatic 
fracture 
Any clinically diagnosed vertebral 
fracture, excluding severe traumatic 
fracture 
Abbreviations: BMI, body mass index; CHS, Cardiovascular Health Study; CPT; Current Procedural Terminology EPIC, European Prospective Investigation of 
Cancer; GP, general practitioner; Health ABC, Health, Aging and Body Composition, HUNT, Nord-Trøndelag Health Study; ICD, international classification of 
disease; InCHIANTI, Invecchiare in Chianti Study; MrOS, Osteoporotic Fractures in Men Study; NA, not appropriate; OPUS, Osteoporosis and Ultrasound 
Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SOF, Study of Osteoporotic Fractures. 
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Appendix table 2. Study quality assessment 
 
Study Design Setting 
Ascertainment 
of exposure 
Covariates available 
for adjustment 
Assessment of fractures  Adjudication 
blinded to 
thyroid 
function 
Median 
(IQR) length 
of follow-up  
Loss to 
follow-
up 
Fractures 
data 
published 
a 
Method used 
Formal 
adjudication 
Busselton 
Health Study 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid and 
anti-osteoporotic 
medication 
ICD9 and ICD10 
coded diagnoses 
in hospital 
discharge 
records 
No NA 
20.0 (17.6-
20.0) 
5% No 
CHS 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-altering and 
anti-osteoporotic 
medication 
Interview and 
hospital records 
reviewed by 
experts 
No NA 
13.0 (7.6-
19.0) 
0% Yes 
EPIC-Norfolk 
Study 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid and 
thyroid-altering 
medication 
Hospital 
discharge coding 
by data linkage 
with NHS central 
register 
Yes Yes 
12.4 (11.7-
13.3) 
1.3% Yes 
Health ABC 
Study 
Prospective 
cohort 
tstudy 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-alterating and 
anti-osteoporotic 
medication 
Interview, 
hospital records 
and other 
documents 
reviewed by 
clinicians 
Yes Yes 
12.7 (8.0-
13.2) 
<5% Yes 
HUNT Study 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid and 
thyroid-altering 
medication 
Hospital and 
radiology records 
reviewed by 
physicians, 
health 
secretaries and 
nurses 
Yes Yes 
12.2 (11.6-
12.8) 
<5% Yes 
InCHIANTI 
Study 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
Hospital records 
and other 
documents 
Yes Yes 9.1 (7.8-9.3) <5% No 
                                                 
a Four cohorts had not published their fractures data in a separate manuscript previously.  
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thyroid-altering and 
anti-osteoporotic 
medication 
Leiden 85-
Plus Study 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-alterating and 
anti-osteoporotic 
medication 
Annual interview 
of treating GP or 
nursing home 
physician and 
review of their 
medical records 
No NA 4.8 (2.2-8.1) <4% Yes 
MrOS 
Random 
sample of a 
prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-altering and 
anti-osteoporotic 
medication 
Interviewed 
reported 
fractures 
centrally 
adjudicated by 
physician 
through 
radiology reports 
or X-rays 
Yes Yes 
11.1 (8.1-
11.8) 
2% Yes 
OPUS 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-altering and 
anti-osteoporotic 
medication 
Interview after 6 
years follow-up, 
validated by 
medical records 
and imaging 
reviewed by 
radiologist 
Yes Yes 6.0 (5.8-6.3) 40% Yes 
PROSPER 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid and 
thyroid-altering 
medication 
Fractures 
documented as 
adverse events 
No NA 3.3 (3.0-3.5) <1% No 
Rotterdam 
Study 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid 
medication 
GP and hospital 
registry records, 
reviewed by 
independent 
medical experts 
Yes Yes 
15.2 (10.4-
16.2) 
<1% Yes 
Sheffield 
Study 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid 
medication 
GP records and 
interviews, if 
confirmed by 
radiology or 
Yes Yes 
10.0 (2.8-
10.1) 
2% Yes 
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orthopedic 
report 
SOF 
Prospective 
cohort 
study 
Population-
based 
study 
Third 
generation 
TSH assay 
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-altering and 
anti-osteoporotic 
medication 
Mail interview, 
with 
confirmation by 
X-rays or written 
report review by 
radiologist 
Yes Yes 
14.3 (9.8-
19.8) 
5% Yes 
Abbreviations: BMI, body mass index; CHS, Cardiovascular Health Study; EPIC, European Prospective Investigation of Cancer; GP, general practitioner; Health ABC, 
Health, Aging and Body Composition; HUNT, Nord-Trøndelag Health Study; ICD, international classification of disease; InCHIANTI, Invecchiare in Chianti Study; IQR, 
interquartile range; MrOS, Osteoporotic Fractures in Men Study; OPUS, Osteoporosis and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly 
at Risk; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone. 
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Appendix table 3. Analysis stratified by publication status of fractures data 
Analysis by thyroid-stimulating hormone categories 
 Hip fracture a Any fracture b Non-vertebral fracture c Vertebral fracture d 
No. of events/ 
participants 
Hazard ratio 
(95% CI)  
No. of events/ 
participants 
Hazard ratio 
(95% CI)  
No. of events/ 
participants 
Hazard ratio 
(95% CI)  
No. of events/ 
participants 
Hazard ratio 
(95% CI)  
Main analysis 610/13,390 1.25 (1.05-1.49)  561/5,587 1.00 (0.83-1.19) 504/5,013 1.04 (0.85-1.26) 60/4,854 1.46 (0.82-2.61) 
Studies with published  
fractures studies 
572/12,460 1.35 (1.13-1.61) 387/4,097 1.16 (0.93-1.43) 423/4,643 1.27 (1.03-1.57) 53/3,977 1.44 (0.79-2.62) 
Studies with unpublished 
fractures data e 
33/865 
0.44 (0.21-
0.90) 
172/2,039 0.70 (0.50-0.96) 79/862 0.54 (0.33-0.91) 7/858 1.17 (0.14-9.88) 
P-value for interaction NA 0.0001 NA 0.17 NA 0.12 NA 0.84 
Analysis by one standard deviation increase in free thyroxinef 
 Hip fracture g Any fracture h Non-vertebral fracture i  Vertebral fracture j 
No. of events/ 
participants 
Hazard ratio 
(95% CI)  
No. of events/ 
participants 
Hazard ratio 
(95% CI)  
No. of events/ 
participants 
Hazard ratio 
(95% CI)  
No. of events/ 
participants 
Hazard ratio 
(95% CI)  
Main analysis 542/20,633 1.24 (1.12-1.37)  1,629/22,977 1.08 (1.02-1.15) 1,273/19,101 1.10 (1.03-1.18) 129/17,711 1.06 (0.86-1.30) 
Studies with published  
fractures studies 
453/17,663 1.25 (1.12-1.40) 1,003/15,192 1.09 (1.01-1.18) 1,031/16,143 1.12 (1.03-1.20) 103/14,741 1.09 (0.67-1.76) 
Studies with unpublished 
fractures datae 
89/2,970 
  1.16 (0.90-
1.89) 
626/7,785 
   1.07 (0.97-
1.17) 
242/2,958 1.03 (0.87-1.20) 26/2,970 1.05 (0.84-1.31) 
P-value for interaction NA 0.59 NA 0.70 NA 0.35 NA 0.89 
                                                 
a Data on hip fractures were available for 12 studies (all but PROSPER) 
b Data on any fractures were available for 9 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, PROSPER, Rotterdam Study, Busselton Health 
Study, SOF, Health ABC Study). 
cData on non-vertebral fractures were available for 9 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, Sheffield Study, 
OPUS, SOF, Health ABC Study). 
d Data on vertebral fracture were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, SOF, Health ABC Study). 
Vertebral fracture was defined as a clinical symptomatic dorsal or lumbar fracture. 
eBusselton Health Study, InCHIANTI Study and PROSPER Study did not previously publish hip fracture data associated with thyroid function in a separate article. 
fFT4was measured in all studies but SOF and Health ABC Study (FT4not measured in participants with TSH within normal range).  
g Data on hip fractures were available for 10 studies with measured FT4 (all but PROSPER). 
h Data on any fracture were available for 7 studies with measured FT4 (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, PROSPER, Rotterdam Study, 
Busselton Health Study). 
i Data on non-vertebral fracture were available for 7 studies with measured FT4(MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, 
Sheffield Study, OPUS). 
j Data on vertebral fracture were available for 5 studies with measured FT4 (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study). 
Vertebral fracture was defined as a clinical symptomatic dorsal or lumbar fracture.  
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Abbreviations: CI, confidence interval; No., number. 
All analyses were adjusted for age (as a continuous variable) and sex.  
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Appendix table4. Risk of any, non-vertebral and vertebral fractures according to thyroid-stimulating hormone 
categories 
 
TSH level 
(mIU/L) 
Any fracturea Non-vertebral fractureb Vertebral fracturec 
No. of events/ 
participants 
Hazard ratio 
(95% CI) 
No. of events/ 
participants 
Hazard ratio 
(95% CI) 
No. of events/ 
participants 
Hazard ratio 
(95% CI) 
   3.50-4.49 
   2.50-3.49 
   1.50-2.49 
   1.00-1.49 
   0.45-0.99 
179/1,769 
376/4,096 
841/9,847 
555/6,105 
382/4,379 
1 (Reference) 
0.98 (0.82-1.17) 
1.01 (0.86-1.19) 
1.07 (0.90-1.27) 
1.00 (0.83-1.19) 
140/1,396 
280/3,301 
650/8,033 
440/5,165 
364/4,121 
1 (Reference) 
0.91 (0.74-1.12) 
0.97 (0.81-1.17) 
1.02 (0.84-1.24) 
1.04 (0.85-1.26) 
16/1,353 
48/3,194 
99/7,752 
56/4,818 
44/3,501 
1 (Reference) 
1.40 (0.80-2.47) 
1.48 (0.87-2.50) 
1.35 (0.78-2.37) 
1.46 (0.82-2.61) 
P-value  for 
trend 
NA 0.56 NA 0.19 NA 0.43 
Abbreviations: CI, confidence interval; Health ABC, Health, Aging and Body Composition; No., number; PROSPER, 
Prospective Study of Pravastatin in the Elderly at Risk; SOF, Study of Osteoporotic Fractures; TSH, thyroid-
stimulating hormone. 
All analyses were adjusted for age (as a continuous variable) and for sex. 
                                                 
a Data on any fractures were available for 9 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, 
PROSPER, Rotterdam Study, Busselton Health Study, SOF, Health ABC Study). 
b Data on non-vertebral fractures were available for 9 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam 
Study, Busselton Health Study, Sheffield Study, OPUS, SOF, Health ABC Study). 
c Data on vertebral fractures were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, 
Busselton Health Study, SOF, Health ABC Study). Vertebral fracture was defined as a clinical symptomatic dorsal or lumbar 
fracture. 
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Appendix figure 1. Flow diagram of the studies assessed for inclusion 
 
Abbreviations: IPD, individual participants data; TSH, thyroid-stimulating hormone. 
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Appendix figure 2. Risk of hip fracture in participants with thyroid-stimulating hormone (TSH) level 0.45-1.49mIU/L, 
compared to the reference group with TSH level 3.50-4.49mIU/L, stratified by sex, age and duration of follow-up 
 
Abbreviations: CI, confidence interval; HR, hazard ratio; No, number; TSH, thyroid-stimulating hormone. 
We present a selected analysis for the TSH categories 0.45-0.99mIU/L and 3.50-4.99mIU/L. Hazard ratios are for TSH 0.45-
0.99mIU/L, compared with the reference group 3.50-4.99mIU/L. The analysis stratified for sex was adjusted for age. All 
other analyses were adjusted for age (as a continuous variable) and sex. 
Data on hip fractures were available for 12 studies (all except PROSPER). 
 
